Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp.
Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital (UZA), Edegem, Belgium.
J Neuropathol Exp Neurol. 2018 Mar 1;77(3):178-192. doi: 10.1093/jnen/nlx114.
Migration of dendritic cells (DC) to the central nervous system (CNS) is a critical event in the pathogenesis of multiple sclerosis (MS). While up until now, research has mainly focused on the transmigration of DC through the blood-brain barrier, experimental evidence points out that also the choroid plexus and meningeal vessels represent important gateways to the CNS, especially in early disease stages. On the other hand, DC can exit the CNS to maintain immunological tolerance to patterns expressed in the CNS, a process that is perturbed in MS. Targeting trafficking of immune cells, including DC, to the CNS has demonstrated to be a successful strategy to treat MS. However, this approach is known to compromise protective immune surveillance of the brain. Unravelling the migratory paths of regulatory and pathogenic DC within the CNS may ultimately lead to the design of new therapeutic strategies able to selectively interfere with the recruitment of pathogenic DC to the CNS, while leaving host protective mechanisms intact.
树突状细胞(DC)向中枢神经系统(CNS)的迁移是多发性硬化症(MS)发病机制中的一个关键事件。虽然到目前为止,研究主要集中在 DC 通过血脑屏障的迁移上,但实验证据表明,脉络丛和脑膜血管也是通向 CNS 的重要门户,特别是在疾病早期阶段。另一方面,DC 可以从 CNS 中退出,以维持对 CNS 中表达模式的免疫耐受,这一过程在 MS 中受到干扰。针对包括 DC 在内的免疫细胞向 CNS 的迁移进行靶向治疗已被证明是治疗 MS 的一种成功策略。然而,这种方法已知会损害对大脑的保护性免疫监视。阐明 CNS 内调节性和致病性 DC 的迁移途径,最终可能会设计出新的治疗策略,能够选择性地干扰致病性 DC 向 CNS 的募集,同时保持宿主的保护性机制完好无损。